4-[5-methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester | 1001067-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[5-methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
• 英文别名: propan-2-yl 4-[5-methoxy-6-[[2-methyl-6-(1,2,4-triazol-1-yl)pyridin-3-yl]amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate
• CAS: 1001067-58-8
• 化学式: C₂₂H₂₈N₈O₄
• 分子量: 468.516
• InChiKey: MPLZECUIFLCJLA-UHFFFAOYSA-N

物化性质

• 沸点：
  642.4±65.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  129
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1H-1,2,4-三唑 、 4-[6-(6-bromo-2-methyl-pyridin-3-ylamino)-5-methoxy-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester 在 copper(l) iodide potassium phosphate 、 N,N'-二甲基乙二胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以14%的产率得到4-[5-methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
  参考文献：
  名称：

  MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO

  摘要：

  本发明涉及4-[5-甲氧基-6-(2-甲基-6-[1,2,4]三唑-1-基吡啶-3-基氨基)-嘧啶-4-氧基]-哌啶-1-羧酸异丙酯，其药学上可接受的盐、溶剂合物和水合物，它们是葡萄糖代谢调节剂。因此，本发明的化合物在治疗与代谢相关的疾病和并发症方面具有用处，如糖尿病和肥胖。 (化学式 I)

  公开号：

  US20090286816A1

文献信息

• Modulators of metabolism and the treatment of disorders related thereto
  申请人：Jones Robert M.

  公开号：US20100004272A1

  公开（公告）日：2010-01-07

  The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及4-[6-(6-甲烷磺酰基-2-甲基-吡啶-3-基氨基)-5-甲基嘧啶-4-氧基]-哌啶-1-羧酸异丙酯、其药学上可接受的盐、溶剂合物和水合物，这些化合物是葡萄糖代谢调节剂。因此，本发明的化合物在代谢相关疾病及其并发症的治疗中是有用的，如糖尿病和肥胖症。
• 4-[5-METHOXY-6-(2-METHYL-6-[1,2,4]TRIAZOL-1-YL-PYRIDIN-3-YLAMINO)-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLC ACID ISOPROPYL ESTER AS MODULATOR OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2051976B1

  公开（公告）日：2010-05-26
• COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2344195A2

  公开（公告）日：2011-07-20
• COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2547339A1

  公开（公告）日：2013-01-23
• Combination therapy for the treatment of diabetes and related conditions
  申请人：Mark Michael

  公开号：US20110263617A1

  公开（公告）日：2011-10-27

  The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto.